United Therapeutics - UTHR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $309.44
  • Forecasted Upside: 13.37%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$272.94
▼ -3.56 (-1.29%)

This chart shows the closing price for UTHR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New United Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UTHR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UTHR

Analyst Price Target is $309.44
▲ +13.37% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is $309.44, with a high forecast of $400.00 and a low forecast of $240.00. The average price target represents a 13.37% upside from the last price of $272.94.

This chart shows the closing price for UTHR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 contributing investment analysts is to moderate buy stock in United Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/1/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/30/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/26/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/24/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/24/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/21/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$280.00 ➝ $300.00Low
5/3/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$218.00 ➝ $240.00Low
5/2/2024OppenheimerBoost TargetOutperform ➝ Outperform$375.00 ➝ $400.00Low
5/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$300.00Low
3/7/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$309.00 ➝ $325.00Low
2/22/2024WedbushReiterated RatingOutperform ➝ Outperform$308.00Low
2/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$300.00Low
2/12/2024The Goldman Sachs GroupUpgradeSell ➝ Neutral$213.00 ➝ $215.00Low
2/5/2024Leerink PartnrsReiterated RatingOutperformLow
2/5/2024SVB LeerinkInitiated CoverageOutperform$330.00Low
12/8/2023Wells Fargo & CompanyInitiated CoverageOverweight$309.00Low
11/2/2023Morgan StanleyLower TargetOverweight ➝ Overweight$318.00 ➝ $314.00N/A
11/2/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$290.00 ➝ $294.00N/A
11/2/2023WedbushReiterated RatingOutperform ➝ Outperform$307.00 ➝ $308.00Low
8/3/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$316.00 ➝ $318.00Low
8/3/2023HC WainwrightReiterated RatingBuy ➝ Buy$300.00Low
8/3/2023WedbushBoost TargetOutperform ➝ Outperform$305.00 ➝ $307.00N/A
8/3/2023LADENBURG THALM/SH SHBoost TargetBuy ➝ Buy$256.00 ➝ $268.00Low
5/4/2023LADENBURG THALM/SH SHLower Target$285.00 ➝ $256.00Low
4/21/2023ArgusLower TargetBuy$300.00 ➝ $280.00Low
4/10/2023UBS GroupLower TargetBuy$330.00 ➝ $310.00Low
4/10/2023Morgan StanleyLower TargetOverweight$320.00 ➝ $316.00Low
2/23/2023JPMorgan Chase & Co.Boost TargetOverweight$265.00 ➝ $280.00Low
2/23/2023Morgan StanleyLower TargetOverweight$330.00 ➝ $320.00Low
2/23/2023HC WainwrightReiterated RatingBuy$300.00Low
2/23/2023LADENBURG THALM/SH SHLower Target$295.00 ➝ $285.00Low
1/11/2023ArgusBoost TargetBuy$250.00 ➝ $300.00Low
12/6/2022Morgan StanleyBoost TargetOverweight$322.00 ➝ $330.00Low
12/6/2022UBS GroupInitiated CoverageBuy$320.00Low
12/5/2022The Goldman Sachs GroupInitiated CoverageSell$230.00Low
11/3/2022JPMorgan Chase & Co.Boost TargetOverweight$240.00 ➝ $265.00Low
11/3/2022Morgan StanleyBoost TargetOverweight$288.00 ➝ $322.00Low
11/3/2022WedbushBoost Target$250.00 ➝ $305.00Low
11/3/2022OppenheimerBoost TargetOutperform$325.00 ➝ $375.00Low
11/3/2022HC WainwrightBoost TargetBuy$255.00 ➝ $300.00Low
10/11/2022Morgan StanleyInitiated CoverageOverweight$288.00Low
9/20/2022Bank of AmericaReiterated RatingUnderperformLow
9/19/2022WedbushReiterated RatingOutperform$263.00Low
5/24/2022Jefferies Financial GroupBoost Target$223.00 ➝ $245.00High
5/24/2022JPMorgan Chase & Co.Boost Target$225.00 ➝ $238.00High
5/24/2022WedbushBoost TargetOutperform$236.00 ➝ $263.00High
5/24/2022Credit Suisse GroupBoost TargetOutperform$219.00 ➝ $247.00High
5/24/2022HC WainwrightBoost TargetBuy$248.00 ➝ $255.00High
5/5/2022OppenheimerBoost Target$275.00 ➝ $300.00Low
4/19/2022JPMorgan Chase & Co.Lower TargetOverweight$230.00 ➝ $223.00High
2/27/2022WedbushReiterated RatingBuy$276.00 ➝ $236.00Medium
2/25/2022HC WainwrightReiterated RatingBuyMedium
2/25/2022LADENBURG THALM/SH SHLower TargetBuy$231.00 ➝ $203.00Low
2/11/2022BTIG ResearchInitiated CoverageNeutralLow
7/14/2021ArgusUpgradeHold ➝ Buy$205.00Low
5/6/2021HC WainwrightBoost TargetBuy$195.00 ➝ $248.00High
4/8/2021JPMorgan Chase & Co.Boost TargetPositive ➝ Overweight$185.00 ➝ $212.00High
2/25/2021WedbushBoost TargetOutperform$255.00 ➝ $260.00Low
2/22/2021Credit Suisse GroupBoost TargetOutperform$169.00 ➝ $196.00Low
2/16/2021OppenheimerBoost TargetOutperform$200.00 ➝ $275.00Low
2/1/2021HC WainwrightUpgradeNeutral ➝ Buy$125.00 ➝ $195.00Low
1/20/2021OppenheimerBoost TargetOutperform$175.00 ➝ $200.00Low
1/20/2021CowenBoost TargetOutperform$160.00 ➝ $200.00Low
1/20/2021LADENBURG THALM/SH SHBoost TargetPositive ➝ Buy$151.00 ➝ $199.00Low
10/29/2020WedbushBoost TargetOutperform$247.00 ➝ $255.00Low
10/29/2020OppenheimerBoost TargetOutperform$165.00 ➝ $175.00Medium
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightHigh
7/30/2020OppenheimerBoost TargetOutperform$155.00 ➝ $165.00Low
7/29/2020WedbushReiterated RatingBuy$243.00 ➝ $244.00Low
6/25/2020WedbushReiterated RatingBuy$243.00High
6/25/2020Credit Suisse GroupBoost TargetOutperform$129.00 ➝ $145.00Medium
6/25/2020HC WainwrightBoost TargetNeutral$85.00 ➝ $125.00Medium
6/24/2020OppenheimerInitiated CoverageBuy$155.00Medium
6/17/2020WedbushReiterated RatingBuy$243.00High
6/12/2020CowenReiterated RatingBuy$145.00Medium
4/30/2020WedbushReiterated RatingBuy$243.00Low
4/30/2020Credit Suisse GroupReiterated RatingBuyLow
3/10/2020Jefferies Financial GroupUpgradeHold ➝ Buy$115.00 ➝ $123.00High
3/4/2020WedbushReiterated RatingBuy$243.00Low
2/27/2020CowenUpgradeMarket Perform ➝ Outperform$119.00 ➝ $145.00High
2/24/2020WedbushReiterated RatingOutperform ➝ Buy$237.00 ➝ $243.00High
2/13/2020Credit Suisse GroupBoost TargetOutperform$113.00 ➝ $121.00Low
2/3/2020WedbushReiterated RatingBuy$237.00Low
1/31/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$116.00 ➝ $120.00Low
1/27/2020WedbushReiterated RatingBuy$237.00High
12/15/2019WedbushReiterated RatingBuy$237.00Medium
12/10/2019Credit Suisse GroupReiterated RatingBuy$113.00Low
12/3/2019Bank of AmericaInitiated CoverageUnderperform$80.00High
11/1/2019HC WainwrightReiterated RatingHold$85.00Low
9/13/2019CowenSet TargetHold$118.00Low
8/1/2019WedbushReiterated RatingBuy$273.00Low
8/1/2019LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$103.00 ➝ $106.00High
8/1/2019Jefferies Financial GroupUpgradeUnderperform ➝ Hold$90.00High
7/1/2019Credit Suisse GroupUpgradeNeutral ➝ Outperform$98.00 ➝ $101.00High
(Data available from 5/24/2019 forward)

News Sentiment Rating

1.29 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2023
  • 9 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2023
  • 23 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 13 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 32 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/24/2024
  • 29 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 40 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2024
  • 47 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/24/2024

Current Sentiment

  • 47 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
United Therapeutics logo
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Read More

Today's Range

Now: $272.94
Low: $270.02
High: $277.27

50 Day Range

MA: $246.55
Low: $228.26
High: $276.50

52 Week Range

Now: $272.94
Low: $204.44
High: $279.98

Volume

107,093 shs

Average Volume

455,290 shs

Market Capitalization

$12.11 billion

P/E Ratio

12.90

Dividend Yield

N/A

Beta

0.54

Frequently Asked Questions

What sell-side analysts currently cover shares of United Therapeutics?

The following sell-side analysts have issued research reports on United Therapeutics in the last twelve months: HC Wainwright, JPMorgan Chase & Co., LADENBURG THALM/SH SH, Leerink Partnrs, Morgan Stanley, Oppenheimer Holdings Inc., StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for UTHR.

What is the current price target for United Therapeutics?

9 Wall Street analysts have set twelve-month price targets for United Therapeutics in the last year. Their average twelve-month price target is $309.44, suggesting a possible upside of 13.4%. Oppenheimer Holdings Inc. has the highest price target set, predicting UTHR will reach $400.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $240.00 for United Therapeutics in the next year.
View the latest price targets for UTHR.

What is the current consensus analyst rating for United Therapeutics?

United Therapeutics currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for UTHR.

What other companies compete with United Therapeutics?

How do I contact United Therapeutics' investor relations team?

United Therapeutics' physical mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company's listed phone number is (301) 608-9292 and its investor relations email address is [email protected]. The official website for United Therapeutics is www.unither.com. Learn More about contacing United Therapeutics investor relations.